Zimmer Biomet price target lowered to $93 from $101 at Canaccord

Canaccord lowered the firm’s price target on Zimmer Biomet (ZBH) to $93 from $101 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and subsequent 10Q release. They noted the company tightened its guidance and reiterated reported growth of 6.7-7.7% with the FNA acquisition expected to contribute roughly 270bps to growth.